<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Optimal treatment of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> may include a combination of antiplatelet and <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> drugs </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated apixaban, a direct and highly selective factor Xa inhibitor, in combination with clinically relevant doses of aspirin and/or <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> for prevention of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> in rabbits </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Studies were conducted in rabbit models of electrically induced carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> and cuticle <z:mp ids='MP_0001914'>bleeding</z:mp> time (BT) </plain></SENT>
<SENT sid="3" pm="."><plain>Apixaban 0.04 and 0.3 mg kg(-1) h(-1) or aspirin 1 mg kg(-1) h(-1) was infused intravenous (i.v.) continuously from 1 h before artery injury or cuticle bleed until the end of the experiment </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> at 3 mg kg(-1) was dosed orally once daily for three days, with the last dose given 2 h before injury </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Control <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight and BT averaged 8.6 +/- 0.9 mg and 181 +/- 12 s, respectively (n = 6 per group) </plain></SENT>
<SENT sid="6" pm="."><plain>Effective doses of apixaban that reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight by 20 and 50% (ED(20) and ED(50)) were 0.04 and 0.3 mg kg(-1) h(-1) i.v., respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Addition of aspirin to apixaban ED(20) and ED(50) significantly reduced the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight from 7.4 +/- 0.5 to 5.3 +/- 0.3 and 3.6 +/- 0.3 mg, respectively, with no significant increases in BT (190 +/- 7 s vs.181 +/- 9 and 225 +/- 11 s, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>Addition of aspirin and apixaban (ED(20) dose) to <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> produced a further significant reduction in <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight from 5.3 +/- 0.3 to 0.7 +/- 0.1 mg </plain></SENT>
<SENT sid="9" pm="."><plain>This combination of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> and aspirin with apixaban (ED(20) dose) produced a significant but moderate BT increase of 2.1 times control </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The combination of apixaban and aspirin or apixaban, aspirin and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> can reduce formation of occlusive <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> without excessive increases in BT in rabbits </plain></SENT>
</text></document>